Hodgkin Lymphoma Mimicking Osteomyelitis

por Majeed, Aneela, Chan, Onyee, Okolo, Onyemaechi, Shponka, Volodymyr, Georgescu, Anca, Persky, Daniel
Publicado 2017

Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma

por Islam, Shariful, Espitia, Claudia M., Persky, Daniel O., Carew, Jennifer S., Nawrocki, Steffan T.
Publicado 2021

Cost-effectiveness and value of information analyses of Bruton’s tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States

por Alrawashdh, Neda, McBride, Ali, Slack, Marion, Persky, Daniel, Andritsos, Leslie, Abraham, Ivo
Publicado 2022

A Rare Presentation of In Situ Mantle Cell Lymphoma and Follicular Lymphoma: A Case Report and Review of the Literature

por Taverna, Josephine, Nair, Anju, Yun, Seongseok, Paulson, Spencer, Schatz, Jonathan H., Persky, Daniel, Fuchs, Deborah, Puvvada, Soham
Publicado 2014

Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI

por Akhenblit, Paul J., Hanke, Neale T., Gill, Alexander, Persky, Daniel O., Howison, Christine M., Pagel, Mark D., Baker, Amanda F.
Publicado 2016

Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2

por Mahadevan, Daruka, Morales, Carla, Cooke, Laurence S., Manziello, Ann, Mount, David W., Persky, Daniel O., Fisher, Richard I., Miller, Thomas P., Qi, Wenqing
Publicado 2014

Synergistic Induction of Apoptosis in High-Risk DLBCL by BCL2 Inhibition with ABT-199 Combined With Pharmacologic Loss of MCL1

por Li, Lingxiao, Pongtornpipat, Praechompoo, Tiutan, Timothy, Kendrick, Samantha L., Park, Soyoung, Persky, Daniel O., Rimsza, Lisa M., Puvvada, Soham D., Schatz, Jonathan H.
Publicado 2015

Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile

por Banh, Cindy, Valsvik, Kendall, Arredondo, Alejandra, Notbohm, Kassie, Elquza, Emad, Babiker, Hani, Kraft, Andrew, Boiles, Alejandro Recio, Persky, Daniel, Ortega, Alicia, McBride, Ali
Publicado 2021

Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma

por Hamlin, Paul A., Musteata, Vasile, Park, Steven I., Burnett, Christine, Dabovic, Kristina, Strack, Thomas, Williams, Eric T., Anand, Banmeet S., Higgins, Jack P., Persky, Daniel O.
Publicado 2022

Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies

por Kittai, Adam S., Best, Scott, Thurlow, Bria, Lam, Vi, Hashiguchi, Taylor, Goodyear, Shaun, Persky, Daniel O., Okada, Craig, Park, Byung, Spurgeon, Stephen E., Danilov, Alexey V.
Publicado 2021

Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs

por Matasar, Matthew J., Luminari, Stefano, Barr, Paul M., Barta, Stefan K., Danilov, Alexey V., Hill, Brian T., Phillips, Tycel J., Jerkeman, Mats, Magagnoli, Massimo, Nastoupil, Loretta J., Persky, Daniel O., Okosun, Jessica
Publicado 2019

Extranodal presentation in limited-stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001

por Stephens, Deborah M., Li, Hongli, Constine, Louis S., Fitzgerald, Thomas J., Leonard, John P., Kahl, Brad S., Song, Joo Y., LeBlanc, Michael L., Smith, Sonali M., Persky, Daniel O., Friedberg, Jonathan W.
Publicado 2022